JUL 03, 2015 8:34 AM PDT

This will only hurt a little! Challenging the Theranos revolution

WRITTEN BY: Kerry Evans
Theranos, founded in 2003 by Elizabeth Holmes, plans to revolutionize clinical laboratory testing by offering low cost blood tests at neighborhood drug stores. Eleftherios Diamandis, head of clinical biochemistry at Mount Sinai Hospital in Toronto, thinks this is too good to be true. He challenges the Theranos model in a recent issue of Clinical Chemistry and Laboratory Medicine.

Theranos offers low cost, direct-to-consumer, laboratory testing.
Theranos testing requires just a few microliters of blood, and more than 30 tests can be performed on a single sample, according to Holmes. Blood is collected from the finger into a disposable cartridge, and loaded into a reader for analysis. However, according to Diamandis, this technology has not been independently evaluated, and no results have been shared in peer-reviewed scientific literature.

Theranos claims to offer the same services as a centralized laboratory, but at a fraction of the cost. Diamandis, however, suspects the cost of reagents and consumables to be similar, if not lower, at centralized labs. Theranos insists that a separate vial of blood is required by centralized labs to perform each blood test. Diamandis disagrees, noting that 10 to 100 analytes can be measured on a 7 ml sample of blood with current (low cost) technology.

Above all, Diamandis is most concerned about the public ordering and interpreting their own blood tests, citing a "lack of appreciation of the dangers of self-screening and self-interpretation of results by asymptomatic individuals who are trying to detect occult disease". What's more, centralized labs phased out the multi-parametric panels used by Theranos in the 1980s because they carry a high rate of false positive results.

Diamandis concludes his critique with a call to openly discuss the Theranos approach in the scientific literature. However, he maintains, "their claims of superiority over current systems and practices are speculative, at best".



Sources: Clinical Chemistry and Laboratory Medicine (CCLM). Volume 53, Issue 7, Pages 989-993 DOI: 10.1515/cclm-2015-0356, May 2015, Business Insider, EurekAlert, EmpowHER, Theranos
About the Author
  • Kerry received a doctorate in microbiology from the University of Arkansas for Medical Sciences.
You May Also Like
MAR 18, 2021
Immunology
COVID Cytokine Storm Chasers Look Inside the Lungs
MAR 18, 2021
COVID Cytokine Storm Chasers Look Inside the Lungs
Immunologists have revealed one of the underlying mechanisms behind COVID’s life-threatening cytokine storms. By s ...
MAR 24, 2021
Cardiology
Supplement Can Prevent Strokes in Patients with Rare Disease
MAR 24, 2021
Supplement Can Prevent Strokes in Patients with Rare Disease
Scientists have found that it may be possible for people with a rare genetic disorder to prevent fatal strokes by taking ...
MAR 26, 2021
Cell & Molecular Biology
New 'Bio-ink' Gets 3D-Printed Organs Closer to Reality
MAR 26, 2021
New 'Bio-ink' Gets 3D-Printed Organs Closer to Reality
For the many people waiting for transplants, 3D-printed organs can't come soon enough. Researchers have been making stri ...
APR 01, 2021
Immunology
The Curious Case of COVID Immunity...a Threat to Vaccination Efforts?
APR 01, 2021
The Curious Case of COVID Immunity...a Threat to Vaccination Efforts?
After COVID infection, there’s a spectrum of diversity in how long antibodies against the coronavirus hang around& ...
MAR 30, 2021
Neuroscience
Prolonged Amygdala Activity Predicts Personal Wellbeing
MAR 30, 2021
Prolonged Amygdala Activity Predicts Personal Wellbeing
Researchers have found that activity in the amygdala (the emotional center of the brain) following exposure to negative ...
APR 15, 2021
Health & Medicine
Concerns Over Delta-8?
APR 15, 2021
Concerns Over Delta-8?
Delta-8-THC is a hemp byproduct that’s being exploited by an apparent loophole in federal law that allows its unfe ...
Loading Comments...